SG/CALL/VERTEX PHARMACEUTICALS/500/0.1/20.09.24

SG/CALL/VERTEX PHARMACEUTICALS/500/0.1/20.09.24 Stock

DE000SU6C4A8

Market Closed - Boerse Frankfurt Warrants 15:37:59 2024-05-31 EDT
1.32 ^EUR	+30.69%

Current month	+148.00%
1 month	+148.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart SG/CALL/VERTEX PHARMACEUTICALS/500/0.1/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480	05-31	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing	05-31	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing	05-29	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing	05-24	MT

More news

Quotes 5-day view

Date	Price	Change
24-05-31	1.24	+22.77%
24-05-30	1.01	-3.81%
24-05-29	1.05	-12.50%
24-05-28	1.2	-13.04%
24-05-27	1.38	+2.99%

Real-time Boerse Frankfurt Warrants

Last update May 31, 2024 at 03:37 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Société Générale
WKN	SU6C4A
ISIN	DE000SU6C4A8
Date issued	2023-12-28
Strike	500 $
Maturity	2024-09-20 (111 Days)
Parity	10 : 1
Emission price	1.49 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	2.55 €
Lowest since issue	0.35 €
Spread	0.03 €
Spread %	2.19%

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company